Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: A randomized, double-blind, right-left arm trial

Acta Dermato-Venereologica

Volumn 93, Issue 5, 2013, Pages 515-519

  Jensen, Jens Michael ^a   Weppner, Merle ^a   Dähnhardt Pfeiffer, Stephan ^b   Neumann, Claudia ^a   Bräutigam, Matthias ^c   Schwarz, Thomas ^a   Fölster Holst, Regina ^a   Proksch, Ehrhardt ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Microscopy Services   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Calcineurin inhibitor; Epidermal barrier; Epidermis; Topical corticosteroid

Indexed keywords

PIMECROLIMUS; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; LAMELLAR BODY; MALE; PRIORITY JOURNAL; PUNCH BIOPSY; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; SKIN WATER LOSS; STRATUM CORNEUM; TRANSMISSION ELECTRON MICROSCOPY;

ADMINISTRATION, CUTANEOUS; ADULT; BIOPSY; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; EPIDERMIS; FEMALE; GERMANY; GLUCOCORTICOIDS; HUMANS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SKIN CREAM; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; WATER LOSS, INSENSIBLE; YOUNG ADULT;

EID: 84883473279     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1533     Document Type: Article

References (24)

1. Bos JD, Kapsenberg ML, Smitt JH. pathogenesis of atopic eczema. Lancet 1994; 343: 1338-1341.
2. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361: 151-160.
3. Morar N, Willis-Owen SA, Moffatt MF, Cookson WO. The genetics of atopic dermatitis. J Allergy clin immunol 2006; 118: 24-34.
4. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein flaggrin are a major predisposing factor for atopic dermatitis. Nat genet 2006; 38: 441-446.
5. Ruether A, Stoll M, Schwarz T, Schreiber S, Fölster-Holst R. Filaggrin loss-of-function variant contributes to atopic dermatitis risk in the population of Northern Germany. Br J Dermatol 2006; 155: 1093-1095.
6. Weidinger S, Illig T, Baurecht H, Irvine AD, Rodriguez E, Diaz-Lacava A, et al. Loss-of-function variations within the flaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy clin immunol 2006; 118: 214-219.
7. Weidinger S, Rodriguez E, Stahl C, Wagenpfeil S, Klopp N, Illig T, et al. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Der-matol 2007; 127: 724-726.
8. Jungersted JM, Scheer H, Mempel M, Baurecht H, Cifuen-Tes L, Høgh JK, et al. Stratum corneum lipids, skin barrier function and flaggrin mutations in patients with atopic eczema. Allergy 2010; 65: 911-918.
9. Burgess JA, Lowe AJ, Matheson MC, Varigos G, Abramson MJ, Dharmage SC. Does eczema lead to asthma? J Asthma 2009; 46: 429-436.
10. Ker J, Hartert TV. The atopic march: what's the evidence? Ann Allergy Asthma Immunol 2009; 103: 282-289.
11. Marenholz I, Nickel R, Rüschendorf F, Schulz F, Esparza-Gordillo J, Kerscher T, et al. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy clin immunol 2006; 118: 866-871.
12. Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-derived TSLp triggers progression from epidermal-barrier defects to asthma. pLoS Biol 2009; 7: e1000067.
13. Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol 2008; 17: 1063-1072.
14. Jensen JM, Fölster-Holst R, Baranowsky A, Schunck M, Winoto-Morbach S, Neumann C et al. impaired sphingo-myelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol 2004; 122: 1423-1431.
15. Jensen JM, Pfeiffer S, Witt M, Bräutigam M, Neumann C, Weichenthal M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009; 123: 1124-1133.
16. Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stütz A, Elbe-Bürger A. corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J invest Dermatol 2004; 122: 673-684.
17. Meingassner JG, Aschauer H, Stütz A, Billich A. pime-crolimus permeates less than tacrolimus through normal, infamed, or corticosteroid-pretreated skin. Exp Dermatol 2005; 14: 752-757.
18. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma immunol 2010; 105: 99-106.
19. Valencia IC, Kerdel FA: Topical steroids. in: K. Wolff et al, Fitzpatrick's dermatology in general medicine, 7th edn. Mcgraw Hill, 2008: 2102-2106.
20. Ainley-Walker PF, Patel L, David TJ. Side to side comparison of topical treatment in atopic dermatitis. Arch Dis child 1998; 79: 149-152.
21. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin res Technol 2001; 7: 73-77.
22. Endo K, Suzuki N, Yoshida O, Sato H, Fujikura Y. The barrier component and the driving force component of tran-sepidermal water loss and their application to skin irritant tests. Skin res Technol 2007; 13: 425-435.
23. Scott IR, Harding CR. Filaggrin breakdown to water binding compounds during development of the rat stratum corneum is controlled by the water activity of the environment. Dev Biol 1986; 115: 84-92.
24. Marsella R, Samuelson D, Doerr K. Transmission electron microscopy studies in an experimental model of canine atopic dermatitis. Vet Dermatol 2010; 21: 81-88.